| News

Tolremo raises additional funding

15.06.2020

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Having raised an additional 4.7 million Swiss francs, Tolremo Therapeutics has now received a total of 13.7 million Swiss francs from a Series A financing round, as detailed in a press release. In addition to the venture capitalists BioMedPartners AG and Altos Venture AG, existing investors such as the Cantonal Bank of Zurich (ZKB) and Redalpine Venture Partners AG have now decided to get involved.

Tolremo develops cancer therapies for precision medicine with the aim of preventing resistances. The successful financing round should now see the first product candidate for clinical development advanced further. Moreover, the development program of the Basel-based company is also set to be expanded.

Resistance against cancer drugs continues to be a major hurdle in achieving long-term patient benefit, explains Stefanie Flückiger-Mangual, Co-Founder and CEO of Tolremo, in the press release. The additional funding will bring the development of resistance-preventing precision therapies for cancer patients one step closer.

Tolremo will also be strengthening its management team. In this context, Reinhard Ambros, the former Global Head of the Novartis Venture Fund, has been named Chairman of the Board. In addition, Guido Hartmann, former Head of Pharmacology at Therachon AG, will join the company in the role of COO/Head Translational Sciences.

Tolremo Therapeutics was also supported by BaseLaunch, which is the Basel Area-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. BaseLaunch is operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency of the Basel Area.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

MTIP using new fund to invest in innovative companies
Basel Area Business & Innovation, Innovation, Invest

MTIP using new fund to invest in innovative companies

The Basel-based firm MTIP AG specializes in investments in HealthTech companies. A total of 130 million euros has already been...

Read More
Basel Area records successful 2020
Basel Area Business & Innovation, Innovation, Invest

Basel Area records successful 2020

Basel Area Business & Innovation was able to newly settle a total of 27 companies in the Basel Area in...

Read More
BetterDoc opts for Basel
Basel Area Business & Innovation, Innovation, Invest

BetterDoc opts for Basel

The online medical service BetterDoc has selected Basel as its Swiss location. Together with the health insurance firm Assura, it...

Read More
RN Laboratories arrives in the Basel Area
Basel Area Business & Innovation, Invest

RN Laboratories arrives in the Basel Area

The global Indian chemicals firm RN Laboratories is establishing a presence in Muttenz. The company will also be building a...

Read More
Kybora settles its European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest

Kybora settles its European headquarters in Basel

The American consultancy Kybora, which operates within the life sciences industry, has established its European headquarters in Basel. Kybora GmbH...

Read More
Escientia establishes subsidiary in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Escientia establishes subsidiary in the Basel Area

The U.S. company Escientia Life Sciences Group has established a subsidiary in the canton of Basel-Landschaft. Escientia Switzerland will offer...

Read More
1 2 3 42

Do you have a question? We'd like to hear from you.